Picture of Spero Therapeutics logo

SPRO — Spero Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapContrarian

Spero Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* Spero Therapeutics Inc  SPRO.OQ  reported a quarterly
adjusted
loss of 24 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -25 cents.  The mean expectation of
three analysts for the quarter was for a loss of 4 cents per
share. Wall Street expected results to range from -12 cents
tozero cents per share.
    * Revenue rose 347.9% to $9.27 million from a year ago;
analysts
expected $21.53 million. 
    * Spero Therapeutics Inc's reported EPS for the quarter was
a loss
of 24 cents​.
    * The company reported a quarterly loss of $12.67 million.
    * Spero Therapeutics Inc shares had fallen by 7.0% this
quarter and gained 8.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 79% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Spero
Therapeutics Inc is $7.50 
This summary was machine generated from LSEG data May 15 at
09:21 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.04          -0.24          Missed
 Dec. 31 2023      -0.10          0.96           Beat
 Sep. 30 2023      -0.03          0.04           Beat
 Jun. 30 2023      -0.34          -0.23          Beat

Recent news on Spero Therapeutics

See all news